Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers

Outcomes in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are poor. Loncastuximab-teserine (Lonca) is an antibody drug conjugate (ADC) which was FDA approved for R/R DLBCL patients who have received at least 2 prior lines of therapy based on the LOTIS-2 trial. Howeve...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Viktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, Kaitlin Annunzio, Aditi Saha, Ning Dong, David Qualls, Behzad Amoozgar, Brad Kahl, John Baird, Pavan Challa, Scott F Huntington, Jennifer Santos, Steven Bair, Mayur Narkhede, Shuning Li, Zachary Frosch, Carrie Ho, Stephen D Smith, Allison Winter, Daniel Landsburg, Fateeha Furqan, Mehdi Hamadani, Katelin Baird, Jason Romancik, Hanan Alharthy, Jennie Law, Leyla Bojanini, Ranjana Advani, Boyu Hu, Patrick Connor Johnson, Natalie S. Grover, Mwanasha Merril, Jennifer L. Crombie, Nazila Shafagati, Cole Sterling, Loretta J. Nastoupil, Narendranath Epperla, Emily C Ayers
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Ferrata Storti Foundation 2024-11-01
coleção:	Haematologica
Acesso em linha:	https://haematologica.org/article/view/11820
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!